RT Journal Article
T1 A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
A1 Doña, Inmaculada
A1 Torres, Maria Jose
K1 Vasodilation
K1 Chronic Disease
K1 Angioedemas, Hereditary
K1 Quality of Life
K1 Bradykinin
K1 Cost of Illness
K1 Capillary Permeability
K1 Andalusian Center for Nanomedicine and Biotechnology-BIONAND
AB Hereditary angioedema (HAE) is a rare inherited chronic disease characterized by unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones, and compromising patient's life. This implies a serious health problem with significant disease burden and reduced life quality. This disease presents a great clinical variability and different endotypes, hampering diagnosis and requiring a personalized treatment. The primary mediator of swelling in most phenotypes is bradykinin, which increases vasodilation and vascular permeability by binding to the bradykinin B2 receptor.
PB John Wiley and Sons
YR 2021
FD 2021-02-23
LK http://hdl.handle.net/10668/17250
UL http://hdl.handle.net/10668/17250
LA en
NO Doña I, Torres MJ. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema. Allergy. 2021 Jun;76(6):1619-1620
DS RISalud
RD Apr 30, 2025